| 摘要 |
<p>The present invention relates to the use of a gastrin compound comprising: Z-Y<Sub>m</Sub>-X<Sub>n</Sub>-AA<Sub>1</Sub>AA<Sub>2</Sub>-AA<Sub>3</Sub>-AA<Sub>4</Sub>-AA<Sub>5</Sub>-AA<Sub>6</Sub>, wherein AA<Sub>1</Sub> is Tyr or Phe, AA<Sub>2</Sub> is Gly, Ala, or Ser, AA<Sub>3</Sub> is Trp, Val, or IIe, AA<Sub>4</Sub> is Met or Leu, AA<Sub>5</Sub> is Asp or Glu, and AA<Sub>6</Sub> is Phe or Tyr the AA<Sub>6</Sub> being amidated; wherein Z is a polymer which when the polymer is a protein, Z is the amino acid sequence of the protein; Y<Sub>m</Sub> is an optional spacer region comprising m amino acid residues of small neutral amino acid, and X is selected from any consecutive portions of : residues 1-28 of SEQ ID NO: 1, residues 1-28 of SEQ ID NO: 2, residues 1-11 of SEQ ID NO: 3, and residuesl-1 of SEQ ID NO: 4, providing that the gastrin compound binds a gastrin/CCK receptor, in the manufacture of a medicament for the treatment of diabetes.</p> |
